Emily B Ehlerding1, Saige Lacognata2, Dawei Jiang2, Carolina A Ferreira3, Shreya Goel4, Reinier Hernandez1, Justin J Jeffery5, Charles P Theuer6, Weibo Cai7,8,9,10. 1. Department of Medical Physics, University of Wisconsin - Madison, 1111 Highland Avenue, Madison, WI, 53705, USA. 2. Department of Radiology, University of Wisconsin - Madison, Madison, WI, USA. 3. Department of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA. 4. Department of Materials Science and Engineering, University of Wisconsin - Madison, Madison, WI, USA. 5. Small Animal Imaging Facility, University of Wisconsin - Madison, Madison, WI, USA. 6. TRACON Pharmaceuticals, Inc., San Diego, CA, USA. 7. Department of Medical Physics, University of Wisconsin - Madison, 1111 Highland Avenue, Madison, WI, 53705, USA. wcai@uwhealth.org. 8. Department of Radiology, University of Wisconsin - Madison, Madison, WI, USA. wcai@uwhealth.org. 9. Department of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA. wcai@uwhealth.org. 10. Department of Materials Science and Engineering, University of Wisconsin - Madison, Madison, WI, USA. wcai@uwhealth.org.
Abstract
PURPOSE: Increased angiogenesis is a marker of aggressiveness in many cancers. Targeted radionuclide therapy of these cancers with angiogenesis-targeting agents may curtail this increased blood vessel formation and slow the growth of tumors, both primary and metastatic. CD105, or endoglin, has a primary role in angiogenesis in a number of cancers, making this a widely applicable target for targeted radioimmunotherapy. METHODS: The anti-CD105 antibody, TRC105 (TRACON Pharmaceuticals), was conjugated with DTPA for radiolabeling with 177Lu (t 1/2 6.65 days). Balb/c mice were implanted with 4T1 mammary carcinoma cells, and five study groups were used: 177Lu only, TRC105 only, 177Lu-DTPA-IgG (a nonspecific antibody), 177Lu-DTPA-TRC105 low-dose, and 177Lu-DTPA-TRC105 high-dose. Toxicity of the agent was monitored by body weight measurements and analysis of blood markers. Biodistribution studies of 177Lu-DTPA-TRC105 were also performed at 1 and 7 days after injection. Ex vivo histology studies of various tissues were conducted at 1, 7, and 30 days after injection of high-dose 177Lu-DTPA-TRC105. RESULTS: Biodistribution studies indicated steady uptake of 177Lu-DTPA-TRC105 in 4T1 tumors between 1 and 7 days after injection (14.3 ± 2.3%ID/g and 11.6 ± 6.1%ID/g, respectively; n = 3) and gradual clearance from other organs. Significant inhibition of tumor growth was observed in the high-dose group, with a corresponding significant increase in survival (p < 0.001, all groups). In most study groups (all except the nonspecific IgG group), the body weights of the mice did not decrease by more than 10%, indicating the safety of the injected agents. Serum alanine transaminase levels remained nearly constant indicating no damage to the liver (a primary clearance organ of the agent), and this was confirmed by ex vivo histological analyses. CONCLUSION: 177Lu-DTPA-TRC105, when administered at a sufficient dose, is able to curtail tumor growth and provide a significant survival benefit without off-target toxicity. Thus, this targeted agent could be used in combination with other treatment options to slow tumor growth allowing the other agents to be more effective.
PURPOSE: Increased angiogenesis is a marker of aggressiveness in many cancers. Targeted radionuclide therapy of these cancers with angiogenesis-targeting agents may curtail this increased blood vessel formation and slow the growth of tumors, both primary and metastatic. CD105, or endoglin, has a primary role in angiogenesis in a number of cancers, making this a widely applicable target for targeted radioimmunotherapy. METHODS: The anti-CD105 antibody, TRC105 (TRACON Pharmaceuticals), was conjugated with DTPA for radiolabeling with 177Lu (t 1/2 6.65 days). Balb/c mice were implanted with 4T1 mammary carcinoma cells, and five study groups were used: 177Lu only, TRC105 only, 177Lu-DTPA-IgG (a nonspecific antibody), 177Lu-DTPA-TRC105 low-dose, and 177Lu-DTPA-TRC105 high-dose. Toxicity of the agent was monitored by body weight measurements and analysis of blood markers. Biodistribution studies of 177Lu-DTPA-TRC105 were also performed at 1 and 7 days after injection. Ex vivo histology studies of various tissues were conducted at 1, 7, and 30 days after injection of high-dose 177Lu-DTPA-TRC105. RESULTS: Biodistribution studies indicated steady uptake of 177Lu-DTPA-TRC105 in 4T1 tumors between 1 and 7 days after injection (14.3 ± 2.3%ID/g and 11.6 ± 6.1%ID/g, respectively; n = 3) and gradual clearance from other organs. Significant inhibition of tumor growth was observed in the high-dose group, with a corresponding significant increase in survival (p < 0.001, all groups). In most study groups (all except the nonspecific IgG group), the body weights of the mice did not decrease by more than 10%, indicating the safety of the injected agents. Serum alanine transaminase levels remained nearly constant indicating no damage to the liver (a primary clearance organ of the agent), and this was confirmed by ex vivo histological analyses. CONCLUSION:177Lu-DTPA-TRC105, when administered at a sufficient dose, is able to curtail tumor growth and provide a significant survival benefit without off-target toxicity. Thus, this targeted agent could be used in combination with other treatment options to slow tumor growth allowing the other agents to be more effective.
Authors: Michael S Gordon; Francisco Robert; Daniela Matei; David S Mendelson; Jonathan W Goldman; E Gabriela Chiorean; Robert M Strother; Ben K Seon; William D Figg; Cody J Peer; Delia Alvarez; Bonne J Adams; Charles P Theuer; Lee S Rosen Journal: Clin Cancer Res Date: 2014-09-26 Impact factor: 12.531
Authors: J H Choe; M J Overman; K F Fournier; R E Royal; A Ohinata; S Rafeeq; K Beaty; J K Phillips; R A Wolff; P F Mansfield; C Eng Journal: Ann Surg Oncol Date: 2015-01-13 Impact factor: 5.344
Authors: Fatima H Karzai; Andrea B Apolo; Liang Cao; Ravi A Madan; David E Adelberg; Howard Parnes; David G McLeod; Nancy Harold; Cody Peer; Yunkai Yu; Yusuke Tomita; Min-Jung Lee; Sunmin Lee; Jane B Trepel; James L Gulley; William D Figg; William L Dahut Journal: BJU Int Date: 2015-06-08 Impact factor: 5.588
Authors: Hao Hong; Yunan Yang; Yin Zhang; Jonathan W Engle; Todd E Barnhart; Robert J Nickles; Bryan R Leigh; Weibo Cai Journal: Eur J Nucl Med Mol Imaging Date: 2011-03-04 Impact factor: 9.236
Authors: Lee S Rosen; Herbert I Hurwitz; Michael K Wong; Jonathan Goldman; David S Mendelson; William D Figg; Shawn Spencer; Bonne J Adams; Delia Alvarez; Ben K Seon; Charles P Theuer; Bryan R Leigh; Michael S Gordon Journal: Clin Cancer Res Date: 2012-07-05 Impact factor: 12.531
Authors: Nikolaos A Dallas; Shaija Samuel; Ling Xia; Fan Fan; Michael J Gray; Sherry J Lim; Lee M Ellis Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: Yin Zhang; Hao Hong; Jonathan W Engle; Jero Bean; Yunan Yang; Bryan R Leigh; Todd E Barnhart; Weibo Cai Journal: PLoS One Date: 2011-12-09 Impact factor: 3.240
Authors: Oliver W Press; Joseph M Unger; Lisa M Rimsza; Jonathan W Friedberg; Michael LeBlanc; Myron S Czuczman; Mark Kaminski; Rita M Braziel; Catherine Spier; Ajay K Gopal; David G Maloney; Bruce D Cheson; Shaker R Dakhil; Thomas P Miller; Richard I Fisher Journal: J Clin Oncol Date: 2012-12-10 Impact factor: 50.717
Authors: Emily B Ehlerding; Carolina A Ferreira; Eduardo Aluicio-Sarduy; Dawei Jiang; Hye Jin Lee; Charles P Theuer; Jonathan W Engle; Weibo Cai Journal: Mol Pharm Date: 2018-05-30 Impact factor: 4.939
Authors: Lei Kang; Cuicui Li; Zachary T Rosenkrans; Nan Huo; Zhao Chen; Emily B Ehlerding; Yan Huo; Carolina A Ferreira; Todd E Barnhart; Jonathan W Engle; Rongfu Wang; Dawei Jiang; Xiaojie Xu; Weibo Cai Journal: Adv Sci (Weinh) Date: 2021-03-15 Impact factor: 16.806